| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803137601045 | 313760104 | VALSARTAN/MYLAN F.C.TAB 40MG/TAB ΒΤx28 (σε OPA-Al-PVC Blister) (σε OPA-Al-PVC Blister) | 3.93 | 4.12 | 5.68 |
| 05/2018 | 2803137602035 | 313760203 | VALSARTAN/MYLAN F.C.TAB 80MG/TAB ΒΤx14 (σε OPA-Al-PVC Blister) (σε OPA-Al-PVC Blister) | 2.37 | 2.49 | 3.43 |
| 05/2018 | 2803137602042 | 313760204 | VALSARTAN/MYLAN F.C.TAB 80MG/TAB ΒΤx28 (σε OPA-Al-PVC Blister) (σε OPA-Al-PVC Blister) | 3.25 | 3.41 | 4.70 |
| 05/2018 | 2803137603032 | 313760303 | VALSARTAN/MYLAN F.C.TAB 160MG/TAB ΒΤx14 (σε OPA-Al-PVC Blister) (σε OPA-Al-PVC Blister) | 2.66 | 2.79 | 3.85 |
| 05/2018 | 2803137603049 | 313760304 | VALSARTAN/MYLAN F.C.TAB 160MG/TAB ΒΤx28 (σε OPA-Al-PVC Blister) (σε OPA-Al-PVC Blister) | 4.00 | 4.20 | 5.79 |
| 05/2018 | 2803137604046 | 313760404 | VALSARTAN/MYLAN F.C.TAB 320MG/TAB ΒΤx28 (σε OPA-Al-PVC Blister) (σε OPA-Al-PVC Blister) | 6.23 | 6.53 | 9.00 |
For the treatment of hypertension.
Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Absolute bioavailability = 23% with high variability
The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.
* 17 L
* 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]